[Nonpsychotic involutional inhibited depressions and psycho-organic deteriorations: treatment with Viloxazine and piracetam].
Involutional depression is often the first symptom of a psycho-organic syndrome or dementia and may not present overt symptoms itself; these depressive states have been variously classified by different schools in various countries. The hypothesis of catecholamine and indolamine in the aetiopathogenic agent is oversimplistic and the theory that abnormal receptor hypersensitivity is the cause of the condition is more convincing. On the basis of this hypothesis numerous studies have been conducted into the efficacy of various antidepressants in the treatment of this hypersensitivity. Involutional depressions are more common among women and are found in about 10% of 60-65 year olds. This report claims that combined viloxazine-piracetam is the most appropriate treatment for involutional depression. This approach (200 mg oral viloxazine and 9 g oral piracetam a day) was adopted for 3 months in 33 out patients about 64 years old who were subsequently put on maintenance doses (100 mg viloxazine, 3 g piracetam a day). The various Hamilton scale parameters were assessed as were reaction times to auditory and visual simple stimuli. Result sat the start and end of treatment were then compared. About three quarters of the patients showed improvement in both depression and psycho-organic syndrome symptoms, while total remission or lasting improvement in both pathologies was obtained in about 50%.
Borromei
A
A
Università di Bologna, Istituto di Clinica Neurologica.
Caramelli
R
R
Conti
M
M
Giancola
L C
LC
Guerra
L
L
D000284:Administration, Oral; D000368:Aged; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D019965:Neurocognitive Disorders / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D010889:Piracetam / Q000009:adverse effects / Q000627:therapeutic use*; D011760:Pyrrolidinones / Q000627:therapeutic use*; D014745:Viloxazine / Q000009:adverse effects / Q000627:therapeutic use*
D009025:Morpholines; D011760:Pyrrolidinones; D014745:Viloxazine; D010889:Piracetam
Depressioni involutive, inibite, non psicotiche e decadimenti psico-organici: trattamento con viloxazina e piracetam.